Michael joined Calyx as Chief Financial Officer in April 2022, bringing a wealth of executive-level experience level in both operations and finance to the organization. Prior to joining Calyx, he worked primarily in IT-enabled service companies that provided support to US federal, state, and local governments as well as commercial entities in the US and internationally. Michael has a proven track record of helping private equity-backed, mid-market companies grow.

 

 

Jamie joined Calyx in January 2020 as the Chief Operating Officer bringing deep, global experience in driving operational excellence and breakthrough financial results. His 25 years’ experience includes a variety of operations, manufacturing, and senior executive roles across the aerospace, engineering, and professional services sectors. Jamie is a Chartered Engineer and holds an MBA from the University of Warwick Business School.

 

 

Stephen Bravo, MD joined Calyx in March 2021, bringing more than 30 years of broad scientific experience to the organization. 其专业知识来源于在备受赞誉的医疗保健中心担任经委员会认证的放射科诊断医生、在顶尖学术机构担任高级教员，以及在众多全球制药公司担任值得信赖的科学顾问。An acknowledged expert in Neuroradiology, Musculoskeletal Radiology, and Interventional Radiology, Dr. Bravo has authored numerous publications and abstracts, holds licenses in three states, and has undertaken the role of principal investigator in over 100 clinical trials.

 

 

Michelle Ronan joined Calyx in April 2022, bringing expertise in developing and executing long-term strategic plans in the global eClinical market. She is an accomplished Head of Corporate Strategy and Development, with significant experience centred around private equity backed businesses, guiding teams through the different stages of a business’ lifecycle. Prior to joining the organization, Michelle consulted with Calyx, identifying opportunities for creating value and driving growth for the business.

John Blakeley joined Calyx as Chief Commercial Officer in January 2020 and brings more than 30 years of senior commercial leadership experience. His expertise in the eClinical solutions space stems from having held C-suite positions at CRF Health, Greenphire, and ERT. John is a seasoned and innovative sales leader who has a successful track record in building high-performing teams to develop creative clinical solutions for customers and drive revenue growth.

 

 

Purvesh Patel joined Calyx in November 2020 leading the Legal, Compliance, Quality, Information Security, Data Privacy and Corporate Development functions. He has nearly 20 years of in-house legal and international corporate transactions experience in highly regulated health and technology sectors. Purvesh has his JD from Case Western Reserve University School of Law and is a trusted business partner relied on by C-suite leaders and Boards to advise on strategic planning, managed growth and governance on a global scale.

 

 

Shelley Latham joined Calyx as Chief People Officer in January 2020 and brings 25 years of experience leading human resources across a broad range of organizations. Prior to joining Calyx, she served as CHRO at Health Trust Europe LLP and held various senior HR positions at Southern Cross Health Care and Beacon Entertainment. Shelley is a Chartered Member of the Institute of Personnel Development and holds an MBA from Nottingham Business School.

 

 

Richard Wallace joined Calyx as Chief Digital Information Officer in February 2021, bringing a wealth of experience from having established and implemented successful business and technology strategies across multiple organizations. Prior to joining Calyx, Richard was Global CIO of Kantar Media & Worldpanel (WPP Group) and has led several R&D transformation projects at IAG / British Airways, G4S & Santander. Richard holds a degree in Economics from the University of Newcastle and an Executive Diploma from the Saïd Business School, University of Oxford.

 

 

Peter 在利用影像和其他生物标志物记录临床试验新药的安全性、疗效和有效性方面拥有丰富的经验。他带领由逾 75 名科学家组成的凯理斯全球科学和医疗服务团队，并积极参与开发和实施适用于全球临床开发项目的高效影像策略。他著作了多篇论文，并定期参加科学会议上提出的研究。

 

在引导凯理斯全球客户的肿瘤学研究的影像工作方面，Oliver 利用其在支持逾 600 项临床试验后获得的经验，其中这些试验涵盖各种不同的适应症、复杂情况并处于开发的各个阶段，他的经验致使逾 20 种肿瘤治疗获得批准。他是《免疫相关疗效标准》（irRC，2009 年）的共同作者、《免疫相关实体瘤疗效评价标准》（irRECIST，2014 年）的第一作者、Eggleton P. 等人《对根据实体瘤疗效评价标准 (RECIST) 与 irRECIST 进行的评价的比较》（2020 年）的共同作者。

 

利用在医学和放射学方面接受过的培训，Surabhi 主导了约 50 项肿瘤学试验（包括实体瘤和血液学恶性肿瘤）的影像部分，并就标准化疗效评估标准的复杂方面提供了咨询。她在多发性骨髓瘤、淋巴瘤和慢性淋巴细胞性白血病 (CLL) 方面的专业知识让她能够为临床试验申办方提供明确的指导，并告知独立审核人关于标准的复杂性，以免产生异质性。

 

Having held senior medical roles at global biopharmaceutical companies and CROs and having worked as an investigator, Manish has a wealth of experience in understanding and executing clinical trials from each stakeholder’s perspective. Manish is a well-established medical and scientific SME for imaging in clinical trial design and execution and has been instrumental in the incorporation of innovative study designs including but not limited to biomarkers including imaging. Manish also has the additional responsibility of leading the Calyx Data Science team focusing on variability analysis, data-driven quality monitoring, and predictive analytics.

 

As the Head of Calyx Musculoskeletal Imaging, Dr. Warner applies her 25+ years of medical imaging research experience and the expertise she’s gleaned from supporting over 200 imaging trials to help pharmaceutical companies and CROs succeed.  She holds certifications by the International Society for Clinical Densitometry (ISCD) as a Clinical Densitometrist and a DXA technologist as well as a Radiology Practicing Technologist License in the state of Utah.  Dr Warner’s musculoskeletal research has included the use of many different modalities for the assessment of bone metabolism including bone histomorphometry, 3-point bending, radiography, ultrasound, DXA, QCT, and high-resolution CT imaging.

 

Manuela is responsible for providing scientific advice on implementing medical imaging into clinical trials, conducting investigator, internal staff, and independent reviewer trainings, supporting the development of independent review charters, providing guidance to R&D and application development in the customization of image analysis software tools, and monitoring independent reviewer performance. Manuela has significant experience in leading and managing the imaging component of multiple neurology and oncology clinical trials, with expertise in applying neuro-oncology image assessment criteria such as RANO, iRANO, LANO, REiNS and volumetric analysis.

 

Farhan applies his extensive training and knowledge in bone loss mechanisms and imaging ‒ both in pre-clinical and clinical settings ‒ to leading and overseeing varied clinical trials involving the musculoskeletal system. He also serves as a subject matter expert in this area, contributing and facilitating protocol reviews as well as imaging-focused discussions with clients as well as consultation and networking with Key Opinion Leaders in the field.